J Pharm Biomed Anal

Comparison of two arylsulfatases for targeted mass spectrometric analysis of microbiota-derived metabolites.

Jain A, Correia MSP, Meistermann H, ..., Löhr JM, Globisch D

J Pharm Biomed Anal 195 (-) 113818 [2021-02-20; online 2020-12-02]

Daniel Globisch SciLifeLab Fellow

STAT3 differential scanning fluorimetry and differential scanning light scattering assays: Addressing a missing link in the characterization of STAT3 inhibitor interactions.

Desroses M, Busker S, Astorga-Wells J, ..., Grandér D, Page BDG

J Pharm Biomed Anal 160 (-) 80-88 [2018-10-25; online 2018-07-17]

Monitoring drug-serum protein interactions for early ADME prediction through Surface Plasmon Resonance technology.

Fabini E, Danielson UH

J Pharm Biomed Anal 144 (-) 188-194 [2017-09-10; online 2017-03-28]

Flow-through cross-polarized imaging as a new tool to overcome the analytical sensitivity challenges of a low-dose crystalline compound in a lipid matrix.

Adler C, Schönenberger M, Teleki A, Leuenberger B, Kuentz M

J Pharm Biomed Anal 115 (-) 20-30 [2015-11-10; online 2015-06-24]

Alexandra Teleki SciLifeLab Fellow

A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma.

Svedberg A, Gréen H, Vikström A, Lundeberg J, Vikingsson S

J Pharm Biomed Anal 107 (-) 186-195 [2015-03-25; online 2014-12-25]

Development and validation of method for TH588 and TH287, potent MTH1 inhibitors and new anti-cancer agents, for pharmacokinetic studies in mice plasma.

Saleh A, Gökturk C, Warpman-Berglund U, Helleday T, Granelli I

J Pharm Biomed Anal 104 (-) 1-11 [2015-02-00; online 2014-11-15]